Show Notes
Could the right treatment pace make all the difference to living well with myeloma? Professor Gordon Cook explores frailty in myeloma, explaining why it is more than age, how fitness can change during treatment, and why treatment should be tailored to the individual. 📌Key Takeaways: Frailty is dynamic - it can change. Age alone doesn't tell the whole story. Myeloma treatment isn't a sprint - it's a marathon.
For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/ We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/ The Myeloma UK InfoLine is: 0800 980 3332 This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns ABOUT YOUR HOSTS Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.
Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients. She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.
More from The Myeloma Minutes
This episode explores the latest advances in myeloma treatment, explaining how the PERSEUS regimen combines four drugs, stem cell transplant and personalised maintenance to help patients achieve deeper, longer-lasting remissions. 📌Key Takeaways: Could remission last 10 years or more? Four drugs, better results - what has changed? Side effects matter: why your treatment can be adjusted.
This episode explores the realities of living with multiple myeloma, from treatment and managing symptoms to maintaining quality of life and finding confidence beyond the diagnosis. 📌Key Takeaways: Myeloma changes life - but it doesn’t have to define it. Small changes can make a big difference to wellbeing. You can still plan, adapt and look forward.
This episode explores the latest breakthroughs from the world's leading myeloma conferences, explaining how new research and clinical trials could shape future treatment and improve patient care with Charlotte. 📌Key Takeaways: Discover the newest treatments that could transform myeloma care in the years ahead. Find out why clinical trials today become tomorrow’s standard treatments. Hear how global collaboration is bringing safer, more effective therapies closer to patients.
This episode explains when DT-PACE chemotherapy is used in myeloma, how it works, what patients can expect during treatment, and why it remains an important bridge to newer therapies. 📌Key Takeaways: Why use older chemotherapy? Sometimes it's the fastest way to get myeloma back under control. DT-PACE is a bridge - helping patients reach treatments like stem cell transplant or CAR T-cell therapy. The treatment is intensive, but careful monitoring helps manage side effects and maximise its benefits.
Experts discuss the approval of the new DVRD four-drug treatment for newly diagnosed myeloma patients who are not eligible for a stem cell transplant, exploring its benefits, risks and how treatment decisions are personalised. 📌Key Takeaways: New four-drug treatment now available in England and Wales Deeper remissions and longer disease control for many patients Why the “best” treatment depends on you, not just the disease